Quotes 5-day view Delayed Swiss Exchange
02/22/2021
02/23/2021
02/24/2021
02/25/2021
02/26/2021
Date
591.2(c)
585.2(c)
592.4(c)
583.8(c)
573.8
Last
178 611
310 483
215 616
169 127
249 448
Volume
-1.60%
-1.01%
+1.23%
-1.45%
-1.71%
Change
Sales 2020
6 161 M
6 800 M
6 800 M
Net income 2020
844 M
932 M
932 M
Net Debt 2020
2 851 M
3 146 M
3 146 M
P/E ratio 2020
50,5x
Yield 2020
0,50%
Sales 2021
4 983 M
5 500 M
5 500 M
Net income 2021
1 073 M
1 184 M
1 184 M
Net Debt 2021
1 790 M
1 976 M
1 976 M
P/E ratio 2021
41,0x
Yield 2021
0,54%
Capitalization
43 370 M
47 991 M
47 868 M
EV / Sales 2020
7,50x
EV / Sales 2021
9,06x
Nbr of Employees
14 000
Free-Float
99,6%
Lonza Group is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows:
- bio-pharmaceuticals and nutritional ingredients (70.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, nutritional ingredients, etc. In addition, the group offers dosage solutions for...
Notations Surperformance© of Lonza Group AG
Trading Rating :
Investor Rating :
All news about LONZA GROUP AG
News in other languages on LONZA GROUP AG
Analyst Recommendations on LONZA GROUP AG
LONZA GROUP AG - 2020
The stock is approaching a major resistance level
BUY
Moderna files for U.S. vaccine authorization, will seek EU nod
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends LONZA GROUP AG
Short Term Mid-Term Long Term Trends Neutral Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
20
Average target price
652,38 CHF
Last Close Price
583,80 CHF
Spread / Highest target
33,1%
Spread / Average Target
11,7%
Spread / Lowest Target
-11,3%
Please enable JavaScript in your browser's settings to use dynamic charts.